Track market-moving stories before they get noisy

On its third-quarter 2026 earnings call, held on Oct. 22, 2026, Medpace (MEDP -1.29%) reported a record number of net new business awards for the period. For long-term investors, contract win rates and cancellation patterns offer crucial signals about core demand in clinical trial management. Three things management said stand out.

1. Net New Business Awards Reached an All-Time HighClient demand remained high, driving quarterly contract awards entering backlog, or contracted work not yet performed, to unprecedented levels.

Net new business awards reached an all time high in the quarter and our last 12-month closing awards was 23.9%.
-- August James Troendle, Chief Executive Officer2. Clinical Failures Replaced Funding Shortages as Main Cancellation DriverProject cancellations now stem primarily from clinical trial safety signals and efficacy results rather than client capital constraints.

Our cancellations now are primarily those of product failure.
-- August James Troendle, Chief Executive Officer3. Formal 2027 Annual Guidance Delays Until FebruaryManagement deferred full-year financial targets to assess fourth-quarter bookings, while noting alignment with current market expectations.

We will provide guidance for 2027 at the end of our Q4 reporting. At the time of our Q4 reporting in February, however, we see no large disconnect between analyst consensus estimates and our current modeling of 2027.
-- August James Troendle, Chief Executive OfficerLooking AheadContract demand is building in core oncology research, and management isn't hiding its satisfaction about booking momentum. The company maintains operational discipline while expanding capacity in Cincinnati. Management is watching cancellation patterns and upcoming award conversions.

I think that Q4, if things go right, it is going to be another record awards.
-- August James Troendle, Chief Executive OfficerPrioritizing execution quality protects long-term project margins as competitive pricing normalizes.

We focus on quality of our deliverables. And I do think that some of the crazy approaches taken by some in the past few years have died out. I think we are kind of back to a normalized environment.
-- August James Troendle, Chief Executive OfficerThe Motley Fool has positions in and recommends Medpace. The Motley Fool has a disclosure policy.

Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT

Company Participants

David Ruhe - Associate Director of Financial Planning & Analysis
August Troendle - CEO, President & Chairman
Kevin Brady - CFO & Treasurer

Conference Call Participants

Michael Cherny - Leerink Partners LLC, Research Division
Jailendra Singh - Truist Securities, Inc., Research Division
Tucker Remmers - UBS Investment Bank, Research Division
Ann Hynes - Mizuho Securities USA LLC, Research Division
Justin Bowers - Deutsche Bank AG, Research Division
Ryan Halsted - RBC Capital Markets, Research Division
David Windley - Jefferies LLC, Research Division
Christine Rains - William Blair & Company L.L.C., Research Division
Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division
Luke Sergott - Barclays Bank PLC, Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, David Ruhe, Medpace's Director of Investor Relations. You may begin.

David Ruhe
Associate Director of Financial Planning & Analysis

Good morning, and thank you for joining Medpace's Third Quarter 2026 Earnings Conference Call. Also on the call today is our CEO, August Troendle; and our CFO, Kevin Brady.

Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements even if estimates change. Accordingly, you should not rely

A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48

On October 21, 2026, Medpace Holdings Inc MEDP shares rose 6.4% to $662.48, continuing a strong upward trend that has seen the stock increase 21.4% over the past year. The stock has traded between $373.00 and $677.90 over the last 52 weeks.

GF Value™ verdict: Current price is $662.48 vs GF Value™ of $539.19, indicating a 22.9% overvaluation. GF Score™ of 96/100 signifies a strong overall assessment of the stock. Insiders sold $467.0M in shares over the past 12 months, with no buying activity noted. Is MEDP Overvalued or Undervalued? Evaluating Medpace Holdings Inc using the GF Value™, the current price of $662.48 is significantly above its intrinsic value estimate of $539.19. This suggests the stock is overvalued by about 22.9%. The GF Valuation label indicates that Medpace is considered modestly overvalued, posing potential risks for investors looking for a margin of safety. The GF Value™ represents GuruFocus' proprietary intrinsic-value estimate, which combines historical trading multiples, previous business growth, and projections of future performance.

The overvaluation implies that investors may face a downside risk if the market corrects or if the company fails to meet growth expectations. Thus, while Medpace holds a strong GF Score™, the valuation metrics indicate caution for prospective investors regarding current market pricing.

How Does MEDP's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 38.9x 31.5x Forward P/E 34.4x - The current P/E ratio of 38.9x is 24% higher than its 5-year median of 31.5x, indicating that the stock is trading above its historical valuation levels. This analysis aligns with the GF Value™ verdict, reinforcing the notion that Medpace is currently overvalued based on its historical performance metrics.

What Does MEDP's GF Score™ Tell Us? The GF Score™ assesses a company's performance across various dimensions, providing investors with a comprehensive view of its overall health and potential. Medpace's GF Score™ of 96/100 is indicative of strong performance, especially in profitability and growth, with both sub-ranks receiving a perfect score of 10/10. However, the valuation rank is more moderate at 6/10, suggesting that while the company is strong in many areas, its valuation may not be as favorable.

Metric Rating GF Score™ 96/100 Financial Strength 6/10 Profitability 10/10 Growth 10/10 Valuation 6/10 Momentum 10/10 The strong scores in profitability and growth reflect Medpace's robust business operations and potential for future expansion. In contrast, the moderate valuation score suggests caution, particularly in the context of its current price being above intrinsic value, indicating that while Medpace is excelling operationally, it is less favorable from a valuation perspective.

What Are Gurus and Insiders Doing with MEDP? Currently, 9 gurus hold shares of Medpace, with 4 increasing their positions and 5 reducing them in recent quarters. This mixed activity reflects a divergence of opinion among institutional investors regarding the stock's future potential. However, the significant insider selling of $467.0M over the past 12 months, with no buying, raises some questions about the confidence of insiders in the stock's future performance. This pattern may signal potential caution for other investors, as insider selling can indicate that those closest to the company are not optimistic about its short-term prospects.

What This Means for Investors In conclusion, based on the analysis of the GF Value™, Medpace Holdings Inc is currently overvalued at a price of $662.48 compared to its intrinsic value estimate of $539.19. The strong performance metrics in profitability and growth are tempered by the valuation concerns, especially in light of significant insider selling. Prospective investors should be aware of these dynamics as they assess their interest in MEDP.

For further details, you can visit the Medpace Holdings Inc MEDP stock page or explore the GF Value™ page.

Frequently Asked Questions What is MEDP's GF Score™?

MEDP's GF Score™ is 96/100, indicating a strong overall assessment with exceptional performance in profitability and growth.

Is MEDP overvalued or undervalued?

MEDP is currently overvalued, with a GF Value™ of $539.19 compared to its current price of $662.48.

What is MEDP's P/E ratio?

MEDP's P/E (TTM) is 38.9x, which is significantly higher than its 5-year median of 31.5x, indicating that it is trading at a premium relative to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025. Backlog as of September 30.

In the latest trading session, Medpace (MEDP - Free Report) closed at $609.89, marking a -1.64% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.

Prior to today's trading, shares of the provider of outsourced clinical development services had gained 4.14% outpaced the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.

The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $708.75 million, indicating a 7.4% upward movement from the same quarter last year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.54 per share and a revenue of $2.84 billion, indicating changes of +14.79% and +12.38%, respectively, from the former year.

Investors should also note any recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Medpace is presently being traded at a Forward P/E ratio of 35.35. This denotes a premium relative to the industry average Forward P/E of 17.86.

It's also important to note that MEDP currently trades at a PEG ratio of 2.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.67.

The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 101, placing it within the top 42% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow MEDP in the coming trading sessions, be sure to utilize Zacks.com.

Medpace (MEDP - Free Report) ended the recent trading session at $602.90, demonstrating a -2.84% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.45%.

Heading into today, shares of the provider of outsourced clinical development services had gained 4.94% over the past month, outpacing the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.

Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to go public on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $708.75 million, indicating a 7.4% growth compared to the corresponding quarter of the prior year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.54 per share and revenue of $2.84 billion. These totals would mark changes of +14.79% and +12.38%, respectively, from last year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace presently features a Zacks Rank of #3 (Hold).

In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 35.38. This valuation marks a premium compared to its industry average Forward P/E of 16.59.

One should further note that MEDP currently holds a PEG ratio of 2.77. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services industry currently had an average PEG ratio of 1.62 as of yesterday's close.

The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 46% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

In the latest trading session, Medpace (MEDP - Free Report) closed at $622.11, marking a +1% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.

Shares of the provider of outsourced clinical development services have appreciated by 3.7% over the course of the past month, outperforming the Medical sector's loss of 0.67%, and the S&P 500's loss of 0.24%.

The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. In that report, analysts expect Medpace to post earnings of $4.45 per share. This would mark year-over-year growth of 15.28%. Meanwhile, the latest consensus estimate predicts the revenue to be $708.75 million, indicating a 7.4% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.

It is also important to note the recent changes to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace currently has a Zacks Rank of #3 (Hold).

With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.12. Its industry sports an average Forward P/E of 16.95, so one might conclude that Medpace is trading at a premium comparatively.

We can additionally observe that MEDP currently boasts a PEG ratio of 2.75. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry currently had an average PEG ratio of 1.59 as of yesterday's close.

The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 99, finds itself in the top 41% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Envestnet Asset Management Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 30.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,802 shares of the company’s stock after selling 40,222 shares during the period. Envestnet Asset Management Inc. owned approximately 0.33% of Medpace worth $49,147,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $1,323,047,000. Wasatch Advisors LP lifted its position in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after acquiring an additional 125,625 shares during the period. State Street Corp lifted its position in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after acquiring an additional 28,666 shares during the period. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after acquiring an additional 38,760 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes MEDP has been the subject of several research analyst reports. Leerink Partners set a $620.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada increased their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $595.20.

Get Our Latest Research Report on Medpace Medpace Stock Performance Medpace stock opened at $618.88 on Monday. The stock has a market cap of $17.27 billion, a PE ratio of 36.28, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The firm’s 50-day simple moving average is $594.65 and its 200 day simple moving average is $516.25. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insiders Place Their Bets In other Medpace news, Director Robert Kraft sold 3,858 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the sale, the director directly owned 955 shares in the company, valued at $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August Troendle sold 27,833 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $621.33, for a total transaction of $17,293,477.89. Following the sale, the chief executive officer owned 389,456 shares in the company, valued at $241,980,696.48. The trade was a 6.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 284,909 shares of company stock valued at $176,097,458 over the last three months. Company insiders own 20.50% of the company’s stock.

Medpace Profile (Free Report)

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Read More Five stocks we like better than Medpace Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind 3 More AI Infrastructure Plays Beyond the Big Names CAVA Stock Slips: Sector Fear or Valuation Reality?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 21,883 shares of the business's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $623.29, for a total value of $13,639,455.07. Following the completion of the transaction, the chief executive officer directly owned 482,390 shares

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.

Integrated Wealth Concepts LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 29.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,287 shares of the company’s stock after selling 936 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Medpace were worth $1,211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. BlackRock Inc. bought a new position in Medpace during the second quarter valued at approximately $1,323,047,000. Geode Capital Management LLC lifted its stake in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the last quarter. Wasatch Advisors LP grew its position in Medpace by 19.4% in the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after acquiring an additional 125,625 shares in the last quarter. Renaissance Technologies LLC grew its position in Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after acquiring an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Medpace by 19.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after purchasing an additional 60,883 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.2% Shares of MEDP stock opened at $615.18 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The business’s 50 day moving average is $584.38 and its two-hundred day moving average is $509.80. The company has a market cap of $17.17 billion, a PE ratio of 36.06, a price-to-earnings-growth ratio of 2.75 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year. Analyst Upgrades and Downgrades MEDP has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Finally, BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $595.20.

Check Out Our Latest Research Report on Medpace

Insider Buying and Selling In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 27,174 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at $347,261,854.05. This represents a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 159,212 shares of company stock worth $97,515,460 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Medpace Profile (Free Report)

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Recommended Stories Five stocks we like better than Medpace Aeluma’s Selloff Could Be Setting Up Its Next Big Move Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip? The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Engineers Gate Manager LP lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 62.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,693 shares of the company’s stock after selling 7,670 shares during the quarter. Engineers Gate Manager LP’s holdings in Medpace were worth $2,485,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in shares of Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after acquiring an additional 13,963,607 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Medpace in the 2nd quarter valued at approximately $1,323,047,000. Geode Capital Management LLC lifted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Wasatch Advisors LP boosted its stake in Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after purchasing an additional 125,625 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance Shares of MEDP stock opened at $595.41 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock’s 50-day moving average is $579.61 and its two-hundred day moving average is $506.17. The firm has a market cap of $16.62 billion, a P/E ratio of 34.90, a PEG ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year. Wall Street Analyst Weigh In MEDP has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Robert W. Baird upped their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $595.20.

Get Our Latest Stock Analysis on Medpace

Insider Buying and Selling at Medpace In other news, Director Robert Kraft sold 3,858 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the transaction, the director owned 955 shares in the company, valued at $590,008.55. This represents a 80.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August Troendle sold 650 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the transaction, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is currently owned by insiders.

Medpace Profile (Free Report)

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Featured Articles Five stocks we like better than Medpace Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Institutional Money Is Pouring Into These 2 Altcoin ETFs The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares 3 Dividend Kings to Buy While They’re Still Beaten Down

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Concentra Group and Medpace are sporting Zacks Ranks of #1 (Strong Buy) and #2 (Buy), respectively, right now. This means that CON's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. However, value investors will care about much more than just this.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

CON currently has a forward P/E ratio of 20.95, while MEDP has a forward P/E of 33.25. We also note that CON has a PEG ratio of 1.26. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. MEDP currently has a PEG ratio of 2.60.

Another notable valuation metric for CON is its P/B ratio of 9.04. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, MEDP has a P/B of 37.52.

These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.

CON has seen stronger estimate revision activity and sports more attractive valuation metrics than MEDP, so it seems like value investors will conclude that CON is the superior option right now.

Bank of New York Mellon Corp bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 146,588 shares of the company’s stock, valued at approximately $77,632,000. Bank of New York Mellon Corp owned 0.53% of Medpace as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. Focus Partners Advisor Solutions LLC acquired a new stake in Medpace during the second quarter valued at approximately $1,685,000. State of Wyoming acquired a new position in shares of Medpace in the 2nd quarter worth approximately $88,000. GSA Capital Partners LLP bought a new position in shares of Medpace during the 2nd quarter worth approximately $208,000. MGO One Seven LLC boosted its stake in Medpace by 7.1% in the 2nd quarter. MGO One Seven LLC now owns 968 shares of the company’s stock valued at $513,000 after buying an additional 64 shares in the last quarter. Finally, Associated Banc Corp acquired a new stake in Medpace in the 2nd quarter valued at $204,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 1.0% Shares of NASDAQ MEDP opened at $614.06 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The firm’s 50-day simple moving average is $556.26 and its 200 day simple moving average is $492.77. The company has a market cap of $17.14 billion, a price-to-earnings ratio of 35.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year. Insiders Place Their Bets In related news, CFO Kevin M. Brady sold 3,400 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the transaction, the chief financial officer owned 12,830 shares in the company, valued at $8,021,829.20. The trade was a 20.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This trade represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 141,639 shares of company stock valued at $83,824,038 over the last quarter. Company insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In MEDP has been the subject of a number of analyst reports. Robert W. Baird lifted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $584.18.

Get Our Latest Report on Medpace

Key Headlines Impacting Medpace Here are the key news stories impacting Medpace this week:

Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions. Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure. Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.” Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence. About Medpace (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Read More Five stocks we like better than Medpace Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Concentra Group and Medpace are both sporting a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. However, value investors will care about much more than just this.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

CON currently has a forward P/E ratio of 21.70, while MEDP has a forward P/E of 35.07. We also note that CON has a PEG ratio of 1.30. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MEDP currently has a PEG ratio of 2.74.

Another notable valuation metric for CON is its P/B ratio of 9.18. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, MEDP has a P/B of 39.5.

These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.

Both CON and MEDP are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that CON is the superior value option right now.

American Capital Management Inc. bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 210,217 shares of the company’s stock, valued at approximately $111,329,000. Medpace makes up about 5.0% of American Capital Management Inc.’s investment portfolio, making the stock its 3rd largest holding. American Capital Management Inc. owned approximately 0.75% of Medpace as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Medpace in the second quarter worth $1,323,047,000. AQR Capital Management LLC lifted its position in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP lifted its position in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 0.8% Medpace stock opened at $619.05 on Thursday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a fifty day simple moving average of $559.49 and a two-hundred day simple moving average of $493.31. The firm has a market cap of $17.28 billion, a price-to-earnings ratio of 36.29, a PEG ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year. Insider Activity In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at approximately $2,302,157.70. The trade was a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 27,174 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares of the company’s stock, valued at $347,261,854.05. The trade was a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 125,290 shares of company stock valued at $76,466,988. Company insiders own 20.50% of the company’s stock.

Medpace News Roundup Here are the key news stories impacting Medpace this week:

Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95. Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target. Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now? Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure. Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst. Wall Street Analysts Forecast Growth A number of equities analysts have weighed in on MEDP shares. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average target price of $584.18.

Read Our Latest Report on MEDP

Medpace Profile (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Articles Five stocks we like better than Medpace Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Allworth Financial LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,894 shares of the company’s stock, valued at approximately $2,062,000.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in Medpace during the second quarter worth $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Madison Asset Management LLC bought a new position in shares of Medpace in the second quarter valued at about $128,956,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In A number of research analysts recently commented on the stock. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $584.18.

Get Our Latest Stock Report on MEDP Insider Buying and Selling at Medpace In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 122,261 shares of company stock worth $71,729,129 over the last quarter. Insiders own 20.50% of the company’s stock.

Medpace Stock Performance Shares of NASDAQ:MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market capitalization of $17.33 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The company has a fifty day moving average of $550.16 and a 200-day moving average of $492.71.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Recommended Stories Five stocks we like better than Medpace Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Abacus FCF Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company’s stock, valued at approximately $6,635,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new position in Medpace in the second quarter worth $27,000. Elyxium Wealth LLC acquired a new position in Medpace during the 4th quarter valued at about $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the 2nd quarter valued at about $31,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace in the second quarter valued at about $34,000. Finally, Basecamp Wealth Advisors LLC raised its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance NASDAQ MEDP opened at $608.27 on Thursday. The company has a market capitalization of $16.98 billion, a PE ratio of 35.65, a P/E/G ratio of 2.63 and a beta of 1.15. The company has a fifty day moving average of $544.34 and a 200 day moving average of $491.59. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year. Insider Buying and Selling In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the sale, the chief executive officer owned 615,802 shares in the company, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 67,195 shares of company stock valued at $37,989,998. Insiders own 20.50% of the company’s stock.

Analyst Ratings Changes MEDP has been the subject of several research analyst reports. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Finally, Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $584.18.

Get Our Latest Report on Medpace

Medpace Profile (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Recommended Stories Five stocks we like better than Medpace Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 11,366 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $601.53, for a total value of $6,836,989.98. Following the completion of the sale, the chief executive officer owned 604,436 shares in the company, valued at $363,586,387.08. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Medpace Price Performance NASDAQ MEDP opened at $578.50 on Monday. The stock has a market capitalization of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.58 and a beta of 1.15. The business has a 50 day simple moving average of $536.23 and a two-hundred day simple moving average of $491.58. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Medpace in the 2nd quarter worth about $1,323,047,000. AQR Capital Management LLC grew its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Madison Asset Management LLC bought a new position in Medpace during the 2nd quarter valued at about $128,956,000. Arrowstreet Capital Limited Partnership raised its position in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Finally, American Capital Management Inc. purchased a new stake in Medpace in the 2nd quarter worth about $111,329,000. Hedge funds and other institutional investors own 77.98% of the company’s stock. Wall Street Analyst Weigh In MEDP has been the subject of several research reports. Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird boosted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $584.18.

Check Out Our Latest Analysis on MEDP

About Medpace (Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Articles Five stocks we like better than Medpace The Metals Company’s Big Bet Now Comes Down to a License OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings Meta and Tesla Are Rebounding From Oversold Levels—Now What? AMG’s Alternatives Boom Powers Record Growth

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employed approximately 6,500 people across 46 countries as of June 30, 2026.

MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. MEDP has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.

Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.47 to $17.51 per share. MEDP also boasts an average earnings surprise of +10.2%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MEDP should be on investors' short list.

Medpace Holdings, Inc. (MEDP - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."

Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.

There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.

A golden cross contrasts with a death cross, another widely-followed chart pattern that suggests bearish momentum could be on the horizon.

Shares of MEDP have been moving higher over the past four weeks, up 9.3%. Plus, the company is currently a #2 (Buy) on the Zacks Rank, suggesting that MEDP could be poised for a breakout.

The bullish case only gets stronger once investors take into account MEDP's positive earnings outlook for the current quarter. There have been 5 upward revisions compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.

Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on MEDP for more gains in the near future.

Key Takeaways Medpace posted record Q2 net new business awards of $795.7 million, lifting book-to-bill to 1.13.MEDP's backlog reached $3.01 billion, with about $1.96 billion expected to convert within 12 months.MEDP's record bookings were helped by lower cancellations, which remain difficult to forecast. Medpace Holdings, Inc. (MEDP - Free Report) regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.

The central issue is timing. Better demand can strengthen backlog and support future growth, but study starts, pre-backlog work and unpredictable cancellations may delay the larger revenue benefit until 2027.  

MEDP Delivers Record Quarterly AwardsNet new business awards increased 28.2% year over year to $795.7 million, the highest quarterly level reported by Medpace. The result lifted net book-to-bill to 1.13, meaning awards exceeded second-quarter revenues.

That was a clear improvement from the first quarter's 0.88 ratio. The rebound indicates that commercial activity recovered enough to replace revenue consumed during the quarter and begin rebuilding forward coverage.

Medpace’s Demand Indicators BroadenRequest-for-proposal activity increased both sequentially and year over year, while win rates recovered after management's improvement initiatives. Client funding activity also remained constructive, supporting a broader opportunity set.

Management expects gross bookings to ramp during the second half. That outlook is relevant across the contract research market, where ICON plc (ICLR - Free Report) provides integrated clinical development services and IQVIA Holdings Inc. (IQV - Free Report) combines clinical research services with healthcare data and analytics. For MEDP, stronger gross awards will matter most if cancellations stay within a reasonable range.

MEDP’s Oncology Mix Reshapes the PipelineOncology represented more than half of second-quarter bookings and initial award notifications. At the same time, new cardiometabolic award activity moderated as several large metabolic programs moved closer to maturity.

The shift reduces reliance on the therapeutic area that recently drove growth and moves the pipeline toward Medpace's historical mix. Yet oncology programs can carry different award, study-start and conversion patterns, leaving the timing of revenue recognition less predictable.

Medpace’s Backlog Supports Revenue ContinuityEnding backlog increased 4.9% year over year to $3.01 billion. Medpace expects approximately $1.96 billion of that backlog to convert into revenues over the next 12 months, providing a meaningful base of contracted work.

The near-term conversion estimate does not capture the full potential of the second-quarter awards. Some programs remain in pre-backlog, while others need additional time before study activity begins. Those lags could push much of the incremental contribution into 2027.

Here's where the consensus estimates for the company's 2026 and 2027 sales currently stand.

Image Source: Zacks Investment Research

MEDP’s Cancellation Risk Clouds the RecoveryLower cancellations accounted for more than half of the sequential improvement in net bookings. That makes the quarterly record less straightforward than the headline figure suggests because part of the rebound came from fewer lost awards rather than gross-booking growth alone.

Management said cancellations cannot be forecast reliably and may arise without warning. A renewed spike could weaken net bookings, slow backlog expansion and delay the expected benefit from the stronger commercial pipeline.

MEDP’s Growth Signals Support Cautious OptimismThe second-quarter recovery improves MEDP's path toward stronger 2027 growth, but execution still depends on converting awards into backlog and starting studies on schedule. The year-to-date book-to-bill ratio of 1.00 also shows that the first-half recovery was balanced rather than decisive.

Image Source: Zacks Investment Research

MEDP currently carries a Zacks Rank #2 (Buy), with a Growth Score of A and a VGM Score of B. Those readings support the stock's growth profile and complement its favorable earnings-revision signal. Still, a Value Score of D and a Momentum Score of C argue for close attention to valuation, backlog conversion and the durability of bookings before drawing a firmer conclusion.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employs approximately 6,200 people across 46 countries as of fiscal 2025.

MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. MEDP has a Momentum Style Score of A, and shares are up 3.5% over the past four weeks.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.47 to $17.51 per share. MEDP boasts an average earnings surprise of +10.2%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MEDP should be on investors' short list.

Posted by Defense World Staff on Jul 28th, 2026

American Capital Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,947 shares of the company’s stock after selling 6,427 shares during the period. Medpace accounts for 5.6% of American Capital Management Inc.’s holdings, making the stock its biggest holding. American Capital Management Inc. owned about 0.76% of Medpace worth $104,656,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of MEDP. NewEdge Advisors LLC raised its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Medpace in the 2nd quarter valued at about $296,000. Finally, M&T Bank Corp increased its stake in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance Shares of MEDP stock opened at $589.37 on Tuesday. The company has a market cap of $16.45 billion, a P/E ratio of 34.55, a PEG ratio of 2.68 and a beta of 1.15. The stock has a 50 day simple moving average of $495.46 and a two-hundred day simple moving average of $493.70. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.

Wall Street Analyst Weigh In MEDP has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $560.92.

View Our Latest Stock Analysis on Medpace

Insider Buying and Selling at Medpace In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 20.50% of the stock is owned by corporate insiders.

About Medpace (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

See Also Five stocks we like better than Medpace AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDynamo Internacional Gestao DE Recursos LTDA. Purchases 4,806,348 Shares of Nu Holdings Ltd. $NU

NEXT HEADLINE »RBC Bearings Incorporated $RBC is American Capital Management Inc.’s 3rd Largest Position

Posted by Defense World Staff on Jul 26th, 2026

Dimensional Fund Advisors LP cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,485 shares of the company’s stock after selling 10,865 shares during the period. Dimensional Fund Advisors LP owned about 1.22% of Medpace worth $167,300,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace during the fourth quarter worth $30,000. Elyxium Wealth LLC acquired a new position in Medpace in the 4th quarter worth $30,000. Quarry LP acquired a new position in Medpace in the 3rd quarter worth $35,000. Finally, Bayban bought a new position in Medpace during the 4th quarter worth about $44,000. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by corporate insiders.

Medpace Price Performance Medpace stock opened at $601.38 on Friday. The firm has a 50-day moving average of $492.09 and a 200-day moving average of $494.49. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a P/E/G ratio of 2.93 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the business earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.

Key Stories Impacting Medpace Here are the key news stories impacting Medpace this week:

Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article Analysts Set New Price Targets MEDP has been the subject of a number of research reports. BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen lifted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $560.92.

Check Out Our Latest Analysis on MEDP

Medpace Profile (Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Further Reading Five stocks we like better than Medpace Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESTERIS plc $STE Shares Acquired by Arrowstreet Capital Limited Partnership

NEXT HEADLINE »Dimensional Fund Advisors LP Increases Stock Holdings in First Hawaiian, Inc. $FHB